CLRB

Cellectar is a pre-revenue, late-stage clinical biopharma whose value rests entirely on its phospholipid-radioconjugate (PRC) pipeline — lead asset iopofosine I-131, plus earlier CLR-125 and CLR-225 programs. There is no product revenue in any year of the provided history, only losses: FY2025 net loss was -$21.8M (an improvement from -$44.6M in FY2024, but that shrinkage was driven by a 56% cut in R&D to $11.5M, i.e. slamming the brakes on spend, not by any commercial traction). ROE of -255% and an accumulated deficit of -$269M underline that this company has never earned a dollar.

The balance sheet is the disqualifier. Cash & equivalents ended FY2025 at just $13.2M, down 43% year-over-year, against operating cash burn of -$23.1M. That is roughly six months of runway. Management itself opens the risk factors with 'We will require additional capital in order to continue our operations and may have difficulty raising additional capital,' and on April 30, 2025 announced it would 'explore a full range of strategic alternatives' — mergers, licensing, partnerships — while making clear the Phase 1 CLR-225 study and the WM NDA submission are 'subject to our ability to obtain additional financing.' A late-stage company shopping itself and gating its own trials on funding is a distress signal, not a growth story. The 90.8% collapse in share count to 4.24M reflects a reverse split, typical of a beaten-down micro-cap fighting delisting; the $-8.35 diluted EPS is a split-adjusted artifact, not a fundamentals win.